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Abstract 
 
Background. Atypical hemolytic uremic syndrome (aHUS) is associated with defective 
complement regulation. Recently, an autoimmune aHUS form has been described that is 
associated with complement factor H (CFH) autoantibodies. The aim of this study was to 
address the pathologic relevance of CFH autoantibodies in aHUS. 
Methods. CFH autoantibodies were identified and antibody levels were analyzed in three 
aHUS patients during disease course by ELISA method. Epitope mapping was performed 
using recombinant factor H fragments and domain mapped monoclonal antibodies. Effect of 
the antibodies on cell protective activity of CFH was measured by hemolytic assays. 
CFH:autoantibody complexes were analyzed by ELISA. 
Results. All three autoantibodies bound to the C-terminal domain of CFH, which is essential 
for CFH binding to cell surfaces. In patient 1, plasma exchanges and immune adsorption 
temporarily reduced the autoantibody titer and led to temporary clinical improvement. In 
patient 2, plasma exchanges and long-term immunosuppression strongly reduced the CFH 
autoantibody level, and induced a stable remission of aHUS. Patient 3 had lower autoantibody 
levels that decreased during follow-up and is in good clinical condition. The patients’ plasma 
samples caused enhanced lysis of sheep erythrocytes and the degree of lysis correlated with 
the CFH autoantibody titer and the amount of CFH:autoantibody complexes. Addition of 
purified CFH to aHUS plasma or removal of IgG inhibited the hemolytic activity. 
Conclusion. These results support a direct role of the autoantibodies in aHUS pathology by 
inhibiting the regulatory function of CFH at cell surfaces and suggest that reduction of the 
autoantibody titer is beneficial for the patients. 
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Short summary: 
This study addresses the role of factor H autoantibodies in autoimmune atypical hemolytic 
uremic syndrome. The levels of free and complexed autoantibodies in patients’ plasma 
samples were analyzed in parallel with the function blocking activity of the autoantibodies. 
The results support a pathogenic role of the autoantibodies by inhibiting the protective activity 
of factor H on cell surfaces during complement attack. 
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Introduction 
 
Hemolytic uremic syndrome (HUS) is a severe kidney disease characterized by 
microangiopathic hemolytic anemia, low platelet count and acute renal failure. The common 
form of this disease (D+ HUS) is usually caused by bacterial infection and is associated with 
diarrhea [1]. The more rare, atypical form of HUS (aHUS or D- HUS), includes both familial 
and sporadic cases, and is associated with dysregulation of complement activation [1,2]. In 
aHUS patients, disease-associated mutations and polymorphisms in complement genes have 
been described for factor H (CFH), membrane cofactor protein (MCP), factor I (CFI), factor B 
and C3 [3,4]. The mutations are generally heterozygous, and most likely the mutant proteins 
cause inappropriate local control of complement activation. Deletion of the factor H-related 
genes CFHR1 and CFHR3 is also associated with aHUS [5]. In addition, CFH autoantibody-
associated aHUS, which has been reported in 6-10% of aHUS-patients, represents an acquired 
autoimmune form of the disease [6,7]. The appearance of CFH-specific autoantibodies is 
linked with the deletion of CFHR1 and CFHR3 [8]. 
 
 CFH is an abundant plasma protein and the major regulator of the alternative 
complement pathway [9]. CFH is composed of 20 short consensus repeat (SCR) domains. The 
N-terminal domains (SCRs 1-4) of CFH mediate cofactor and decay accelerating activities 
[10,11], and the C-terminal domains (SCRs 19-20) contain binding sites for C3b, heparin and 
endothelial cells [12-14]. Thus, the complement regulatory region and the recognition region 
responsible for cell attachment of CFH are spatially separated. SCRs 19-20 represent a hot 
spot for aHUS-associated CFH mutations [15]. Several of these mutations have been shown to 
reduce CFH binding to C3b and to cellular surfaces [16-18]. Functional studies have 
demonstrated that an intact C-terminus is necessary for CFH to bind and exert its complement 
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regulatory activity on cell and tissue surfaces, thus, for full-scale protection of host cells 
against the activated complement system [19-22]. 
 
We have previously mapped the binding sites of CFH autoantibodies to the same C-
terminal domains of CFH, i.e. SCRs 19-20, where most of the aHUS-associated CFH 
mutations occur. In an in vitro hemolytic assay, the autoantibody positive plasma of one 
patient caused enhanced lysis of sheep erythrocytes [7]. This suggests that CFH 
autoantibodies inhibit CFH complement regulatory activity on cell surfaces. 
 
In order to elaborate on the suggested pathomechanism and to assess the clinical 
significance of CFH autoantibodies in aHUS, we have followed the titer and activity of the 
autoantibodies during the disease course of aHUS patients. 
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Subjects and Methods 
The studies have been approved by the Research Ethics Committee of the Medical Faculty of 
Friedrich Schiller University, and were performed in accordance with the Declaration of 
Helsinki.  
 
Sample collection and analyses of anti-CFH autoantibodies 
Plasma samples, collected with informed consent, were analyzed for the presence of CFHR1 
and CFHR3 by Western blot [8]. CFH autoantibodies were identified as described [7]. The 
IgG isotypes were determined using IgG1-, IgG2-, IgG3- and IgG4-specific mouse mAbs 
(Sigma-Aldrich, Taufkirchen, Germany) and HRP-conjugated rabbit anti-mouse Ig 
(DakoCytomation, Hamburg, Germany). IgG was isolated from plasma using Protein G 
columns (GE Healthcare, Freiburg, Germany). The binding domains of the autoantibodies 
were determined using recombinant CFH fragments as described [7]. For inhibition 
experiments, immobilized CFH was preincubated with CFH-specific goat antiserum (Merck 
Biosciences, Schwalbach, Germany), rabbit antisera raised against SCRs 1-4 [23] and SCRs 
19-20 of CFH [24] (both diluted 1:100) or with domain mapped, CFH-specific monoclonal 
antibodies [7,14]. 
 
Determination of CFH autoantibody titer in patients’ plasma 
Plasma samples were incubated on CFH-coated wells in serial dilutions. The titer was 
determined in comparison with a reference sample of patient 1, taken 10 months after initial 
disease onset, and is expressed in arbitrary units as described by Dragon-Durey et al. [6]. This 
sample was compared to a reference with 1000 AU/ml [6], kindly provided by Dr. Dragon-
Durey, and had essentially the same titer (1014 AU/ml). 
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Hemolysis assays 
Hemolysis assays were performed as described using sheep erythrocytes (BioTrend 
Chemikalien, Cologne, Germany) [7]. Some samples were incubated with Protein G beads for 
5-15 min at 20°C to deplete IgG. Hemolytic effects of the CFH-specific mAbs (50 µg/ml) 
were measured using 10% C2-depleted plasma (Merck) in order to prevent activation of the 
classical complement pathway. 
 
Measurement of autoantibody:CFH complexes 
Immune complexes were captured on microtiter plate wells coated with the anti-CFH mAb 
M15 at 5 µg/ml. After blocking, serial plasma dilutions were incubated for 1 h at 20°C and 
bound complexes were detected using HRP-conjugated anti-human IgG (Sigma-Aldrich). 
Bound CFH was detected using a CFH antiserum. 
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Results 
 
Case descriptions 
Patient 1 
Patient 1, a 10-year-old boy (patient #564 in ref. 7), was admitted to hospital at the age of 6.5 
years with kidney failure, and was later diagnosed with aHUS. ADAMTS13 activity was 
normal. Both serum and stool were negative for enterohemorrhagic E. coli. Two weeks after 
disease onset he received ten plasmapheresis in 19 days. Disease recurrence with increase of 
creatinine, low complement C3 levels and increased C3d occurred 4 mo later and was treated 
with seven plasma exchanges in a 2-wk period. A second recurrence occurred 3 mo later. 
Plasma infusions (three times in 10-d intervals) did not improve renal function, therefore the 
presence of CFH autoantibodies was postulated. Plasma exchange was resumed (ten times in 
13 d) with hemodialysis three times. Additionally, immunosuppressive therapy was initiated 
(mycophenolate mofetil 2×250 mg/day, later 2×500 mg/day for 2 months). Rituximab (375 
mg/m2) was applied three times at 3-wk intervals started at 11 mo. Because of unsatisfactory 
efficacy, this was followed by cyclophosphamide treatment three times at 3-wk intervals. 
Plasma exchanges were performed six times within one week at 12 mo, then seven times in 12 
days at 14 mo. A short trial with immunadsorption was stopped because of allergic reaction. 
42 mo after disease onset, the patient remains on peritoneal dialysis, which was changed from 
hemodialysis because of catheter infection and sepsis. It is of note that C3 and C3d levels are 
normal. Genetic analysis showed that in the CFH gene this patient is homozygous for the C 
allele of the c.921A>C polymorphism (A307A in SCR5) [25,26] and has the H4 haplotype 
[27]. In the CFI gene a heterozygous G818A transition (S268S) was found, which is a non-
disease causing polymorphism [28]. The patient lacks CFHR1 and CFHR3. 
 
Patient 2 
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Patient 2 is an 8.5-year-old girl, who presented with D- HUS at the age of 6.8 years. She was 
treated with seven plasma exchanges and received immunosuppressive therapy with 
mycophenolate mofetil and prednisolone. Remission of aHUS was achieved and renal 
function returned to normal. On immunosuppression and antihypertensive treatment she has 
remained free from recurrences up to now. The patient lacks the CFHR1 and CFHR3 proteins. 
 
Patient 3 
Patient 3 is a 12.5-year-old boy who presented with D- HUS at the age of 5 years. At the early 
phase of the disease he was treated with hemodialysis and received plasmapheresis on every 
second day (7 sessions) followed by weekly transfusion of fresh frozen plasma for a period of 
3 months. His kidney functions rapidly improved and have since been stable with endogenous 
creatinine clearance of 35-50 ml/min/l.73m2. He is in good clinical condition without clinical 
or laboratory evidences of hemolysis and with complement levels in the normal range. He is 
on protein-restricted diet, on combined antihypertensive therapy and receives NaHCO3 and 
CaCO3 supplements. Retrospective analysis of his initial plasma samples revealed lack of 
CFHR1 and CFHR3 and the presence of CFH antibodies. 
 
Individual samples from three additional autoantibody positive patients (aHUS1-
aHUS3), described before [8], were also used in hemolytic assays. These patients, who were 
treated with plasmapheresis, lack CFHR1 and CFHR3 [8]. 
 
Characterization of the CFH autoantibodies 
All three patients, but not their family members, have CFH autoantibodies (Figure 1 and 
data not shown). The anti-CFH IgG of patient 1 was characterized before [7]. The three 
autoantibodies were of IgG3 isotype. Reactivity of the autoantibodies with recombinant CFH 
fragments was measured by ELISA in order to localize the binding domain. The 
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autoantibodies bound only to the CFH fragment that includes the most C-terminal SCR20 
domain, i.e. SCRs 15-20. Binding of the autoantibodies to CFH was inhibited by C-terminally 
binding mAbs (C18, C14 and C02), but not by mAbs that recognize the N-terminus (N11) or 
the middle region of CFH (M12, M13, M15). Likewise, polyclonal antibodies against SCRs 
19-20 and against full-length CFH reduced autoantibody binding, whereas an antibody 
specific to SCRs 1-4 did not affect autoantibody binding to CFH (Figure 1 and data not 
shown). No complete inhibition of autoantibody binding could be achieved with mAb C02 in 
the case of patient 2, indicating that despite the same binding domain on CFH, the exact 
binding epitope is different in this patient. Thus, CFH autoantibodies from the three unrelated 
patients have similar characteristics, because they are of the same isotype and bind to the 
same domain on CFH. 
  
CFH autoantibody levels during disease course 
To assess the relevance of the CFH autoantibodies in aHUS, the autoantibody titer was 
followed during treatment of the patients. In patient 1, plasma exchanges temporarily reduced 
the CFH autoantibody titer (Figure 2A), which was accompanied with temporarily 
normalized C3 levels and improvement in clinical parameters (Table 1). Immunosuppressive 
therapy was attempted to reduce the amount of circulating anti-CFH IgG, but the titer 
remained high. Although immune adsorption was effective in reducing the CFH autoantibody 
titer (from 982 to 219 AU/ml), the treatment had to be stopped because of allergic reaction. 
This was followed by an increase in circulating autoantibodies and the patient’s kidney 
function deteriorated. At present, the patient has persistently high titers (707-1244 AU/ml in 
the last 6 mo) and remains on peritoneal dialysis. In patient 2, the autoantibody levels were 
strongly reduced after initial plasma exchanges and immunosuppressive treatment, and 
remained low with little variation during the follow-up period (<100 AU/ml in the last 15 mo) 
(Figure 2B). C3 level and clinical parameters normalized. Patient 3 had lower autoantibody 
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level which decreased during follow-up (Figure 2C) and remains in good clinical condition 
with normal complement levels. 
 
CFH autoantibodies inhibit CFH cell protective activity 
To elaborate on the suspected inhibitory role of the autoantibodies in protection of cellular 
surfaces by CFH against complement attack, hemolysis of sheep red blood cells (SRBC) was 
measured in the presence of patients’ plasma as described [7]. This assay allows measurement 
of complement alternative pathway activity on cell surfaces. Incubation with CFH 
autoantibody positive plasma samples resulted in enhanced hemolysis of SRBC in all tested 
cases (n = 6), including the three patients and additional samples from patients described 
before (Figure 3A) [7,8]. The sample of patient 3 with relatively low autoantibody titer 
showed the smallest hemolytic effect. In contrast, normal human plasma samples showed 
background lytic effect. SRBC lysis was dose-dependently inhibited by addition of purified 
CFH to patients’ plasma in all cases (data not shown). To determine if CFHR1/CFHR3 
deficiency alone influences hemolytic activity, additional assays were performed with 
samples of CFHR1/CFHR3 deficient individuals who lack autoantibodies. These samples 
caused no enhanced hemolysis (Figure 3B). The role of CFH was further confirmed using 
CFH-specific mAbs. Among these antibodies, only the C-terminally binding mAbs C18, C02 
and C14, which have overlapping binding epitopes on CFH and compete with the 
autoantibodies for CFH binding (Figure 1) [7], caused enhanced SRBC lysis when added to 
normal human plasma (data not shown) or to C2-depleted plasma, which was used to exclude 
classical pathway mediated lysis (Figure 3C). 
 
The in vitro hemolytic activity of aHUS plasma correlates with the autoantibody titer 
We next addressed the question whether the different autoantibody titers indeed result in 
variation of hemolytic activity of the patients’ plasma. Samples taken at different time points 
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from aHUS patients were analyzed for both CFH autoantibody titer and hemolytic activity. 
The extent of SRBC lysis in all three analyzed cases followed the changes in autoantibody 
titer and was lower when the titer dropped (Figure 4). The isotype and the binding epitope of 
the autoantibodies were the same at the analyzed time points (data not shown). Because large 
differences in the C3 and CFH levels in the samples may influence the extent of hemolysis 
[19], these parameters were also determined. The C3 and CFH values of the analyzed samples 
showed no correlation with hemolysis (Figure 4). 
 
To directly address the role of the autoantibodies, the lytic effect of patients’ plasma 
before and after IgG depletion was compared. Preincubation of patients’ plasma with Protein 
G beads resulted in reduced SRBC lysis, depending on the duration and thus the extent of IgG 
depletion, and reached background level after 15 min depletion (Figure 5A). This IgG 
depletion results in an artificial reduction of autoantibody titers and the data indicate that the 
same plasma samples with the same C3 and CFH levels cause hemolysis to different extents 
depending on the amounts of autoantibodies remaining in plasma. The same results were 
obtained with all three analyzed autoantibody positive patients’ samples. Furthermore, when 
adding the C-terminally binding C18 mAb to the IgG-depleted plasma or to control normal 
human plasma, the lysis increased again (Figure 5B). This also shows that after IgG depletion 
the complement system in plasma remains active, and the reduced lysis is due to the removal 
of anti-CFH IgG and not to an unspecific complement inhibitory effect. Thus, inhibition of 
CFH surface recognition functions by the autoantibodies results in inappropriate protection of 
cells against complement attack. 
  
CFH:autoantibody complexes in patients’ plasma 
Analysis of autoantibody titers as described above determines only free IgG autoantibodies 
that recognize immobilized CFH. To analyze CFH:anti-CFH complexes in patients’ plasma, 
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serial dilutions of plasma samples were incubated in microtiter plate wells coated with the 
anti-CFH mAb M15 that binds outside the CFH C-terminus (within SCRs 11-18) [14], and 
immune complexes were detected with anti-human IgG. A dose-dependent binding of the 
CFH:autoantibody complexes was observed and at lower autoantibody levels the amounts of 
immune complexes were also reduced (Figure 6A). In patient 3, the autoantibody titers were 
lower than in the other two patients and changed little over time (Figure 2). Likewise, the 
amounts of CFH:autoantibody complexes were similar in the plasma samples, also indicating 
no significant change in the affinity of the autoantibodies. Upon IgG-depletion the immune 
complexes disappeared (shown for patient 3 in Figure 6B). This is in parallel with the 
reduced hemolytic activity of the IgG-depleted plasma samples (Figure 5), and further 
supports the CFH inhibitory role of the autoantibodies in cellular protection. 
 
Because mAb C18 and the autoantibodies have overlapping binding sites on CFH, this 
mAb can catch free CFH only. Therefore, comparison of measured CFH levels using mAbs 
C18 for free and M15 for total CFH allowed to estimate the amounts of free and complexed 
CFH (Figure 6C). In the sample of patient 2 with high titer (1325 AU/ml) approximately 
75% of CFH was in complex with antibodies, in comparison with ca. 20% in the sample with 
low titer (361 AU/ml). In the sample of patient 3 with higher titer (867 AU/ml) ca. 30% of 
CFH was in complex, whereas the amount of complexes were reduced to half in the low titer 
sample (539 AU/ml), which also had weak hemolytic effect (Fig. 3A). Thus indicating that 
the affinity of autoantibodies for CFH is lower in patient 3 than in patient 2. 
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Discussion 
 
Experimental evidence and genetic analyses over the past years established that the delicate 
balance of complement activation and regulation is disturbed in the affected individuals and is 
involved in the pathogenesis of aHUS [1-3]. Apparently, aHUS is a multifactorial disease, 
with multiple predisposing genetic factors and the requirement of an environmental trigger, 
most often infection [29]. 
 
The role of the C-terminus in targeting CFH complement regulatory activity to host 
cells is supported by functional studies [20-22] and by a mouse model of aHUS [30]. In 
addition, sera derived from aHUS patients with C-terminal CFH mutations show reduced 
protection of sheep erythrocytes in a complement-dependent lysis assay [19,31].  
 
The CFH autoantibodies analyzed in this and in earlier studies bind to the most C-
terminal domain of CFH, i.e. SCR20 (Figure 1) [7,8]. Cell survival assays show that aHUS-
associated autoantibodies cause similar functional defects as those described for mutant CFH 
proteins and affect C-terminus-dependent complement regulatory function of CFH. Sheep red 
blood cells, which have surface polyanionic molecules similar to human cells and which lack 
human membrane complement regulators, rely on CFH binding and CFH regulatory activity 
to evade human complement. Thus, when using human plasma in hemolytic assays, sheep 
erythrocytes are protected by bound human CFH and are not lysed. By contrast, plasma 
samples of aHUS patients that contain blocking autoantibodies cause hemolysis (Figure 3A). 
This in vitro hemolytic effect can be inhibited by the addition of excess CFH, or by depletion 
of IgG from the plasma which indicates normalized CFH regulatory function on cellular 
surfaces after removal of CFH autoantibodies (Figure 5). 
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 The same hemolytic effects are achieved through mAbs that share binding epitopes 
with the autoantibodies (Figure 3C). Reduced C3b binding of CFH and impaired C3b 
inactivation on the cell surface, which result in enhanced complement activation and cell 
damage, are caused by mAbs C02, C18 and C14 [21]. These mAbs cause enhanced SRBC 
lysis when added to normal human plasma or to IgG-depleted plasma of autoantibody positive 
aHUS patients (Figure 5). Altogether these data point to the importance of cell protection by 
surface bound CFH under normal, physiological conditions, and show that this mechanism 
does not function properly in aHUS patients with C-terminal CFH mutations or with CFH 
autoantibodies. The fenestrated endothelium in the kidney appears particularly sensitive to 
self-attack, thus the loss of full-scale complement control due to CFH dysfunction leads to 
complement-mediated damage [32]. 
 
The hemolytic assay is a useful tool to analyze CFH functional defects, either caused 
by C-terminal mutations or by autoantibodies. This assay has the advantage that it directly 
evaluates the cell surface activity of CFH, which is relevant in aHUS [7,19,31]. In contrast, 
fluid-phase assays may not be informative, because CFH function in plasma is usually normal 
in the patients [6,7,22]. However, the hemolytic assay can lead to false negative results, for 
example, if C3 is largely consumed, and therefore the plasma has low complement activity. 
Thus, the extent of lysis induced by plasma samples depends on the autoantibody titer and 
affinity, the individual CFH level and the complement status, and it is important to collect and 
handle the samples properly so as they are suitable for such assays. In the analyzed samples, 
CFH levels varied only little, and C3 levels were sufficient for complement activation, as 
shown by the use of mAb C18, and the hemolytic effect was dependent on the presence and 
amounts of autoantibodies in plasma (Fig. 3-5). 
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The three autoantibodies analyzed here had the same characteristics, because they 
were of the same isotype and bound on the same domain of CFH. There were differences, 
however, between the patients regarding the time of diagnosis of the autoantibodies and the 
applied treatment. In the two patients, where the autoantibody levels were permanently 
reduced, there was also improvement in kidney funtion. In patient 1, autoantibodies persist at 
high levels despite several attempted treatments and the patient progressed to end-stage renal 
failure. 
 
 The direct role of the autoantibodies in inhibiting CFH cell protective function and 
correlation of the autoantibody titer with cell damaging effects (Figures 3-5) suggest that 
attempts to remove the autoantibodies from the patients’ circulation represent a rational 
therapeutic approach. Recently, plasma exchanges and rituximab were successfully applied 
before kidney transplantation of an aHUS patient with CFH autoantibodies [33]. Similarly, in 
a patient plasma exchanges and immunosuppression as post-transplant management resulted 
in the disappearance of autoantibodies and a favorable outcome [34]. In addition, purified or 
plasma-derived CFH might be beneficial by increasing the concentration of antibody-free 
CFH. Plasma exchanges, although temporarily remove CFH autoantibodies (Figure 2 and 
Table 1) [6,33,34], might also have a boosting effect in the long term on autoantibody 
production by introducing free CFH antigen. Aiming to reduce the amount of autoantibodies, 
by e.g. immunosuppressive therapies and/or immune adsorption, and intravenous IgG (IVIg) 
infusion, likely represents a better option and eliminates the above risk. It remains to be 
shown how and when CFH autoantibodies appear, and whether autoantibody generation is 
directly influenced by the lack of the CFHR1 and CFHR3 proteins. 
 
Even though we could analyze only a few cases in detail in the present study, the 
results support a pathogenic role of the CFH autoantibodies in aHUS. Because of the similar 
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binding sites and hemolytic effects of the autoantibodies analyzed so far [7,8,31], these results 
likely apply in general. Further clinical studies involving more patients are required to better 
understand the role of autoantibodies and to determine which treatment is most suitable and 
effective in this patient group. 
 
In conclusion, the data reported here demonstrate that there is a direct connection 
between the presence and level of CFH autoantibodies and the extent of CFH functional 
defect at cell surfaces, indicating that CFH autoantibodies contribute to the pathology of 
aHUS. 
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 Table 1 
Laboratory parameters of patient 1 at selected time points. 
time point after 
disease onset 
anti-CFH 
IgG 
(AU/ml) 
[< 100]* 
C3 
(mg/ml) 
[0.7-1.2]* 
C3d 
(mU/L) 
[< 40]* 
platelet count 
(×109 L-1) 
[150-450]* 
LDH 
(IU/L) 
[105-
333]* 
serum creatinine 
(mg/dl) 
[0.2-1.0]* 
at onset 2282 0.8 60 36 2336 2.16 
mo 9.5 ND 0.6 ND 62 689 3.46 
mo 10, after PEx 1132 0.7 41 331 240 2.80 
mo 12 2116 0.4 41 243 229 2.56 
mo 12, after PEx 806 0.7 26 329 209 2.69 
mo 14 1487 0.3 ND 146 425 3.70 
mo 14, after PEx 675 0.8 29 292 307 2.90 
 
ND: not determined; PEx: plasma exchange therapy. Anti-CFH IgG titer is expressed in 
arbitrary units (AU/ml). *normal ranges 
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Legends to figures 
Figure 1. Characterization of CFH autoantibodies of patients 2 and 3. 
(A) CFH autoantibodies were determined by ELISA. The binding of IgG from plasma 
samples to CFH and to BSA as a control was compared to exclude false positivity, as in the 
case of the sister of patient 3. Unrelated control samples (NHS1 and NHS2) were used as 
negative controls. (B) Determination of IgG isotype of the autoantibodies using CFH-coated 
plates and isotype-specific mAbs. As positive control, binding of the isotype-specific mAbs 
on immobilized human IgG is shown. (C) Binding of the autoantibodies to immobilized 
recombinant CFH fragments representing various SCR domains and covering the full length 
of CFH and to purified CFH. (D) Competition assay with CFH-specific antibodies raised 
against the whole molecule (anti-CFH), against SCRs 1-4 (anti-1-4) or SCRs 19-20 (anti-19-
20), or with monoclonal antibodies binding to the C-terminus (C18, C14, C02), the middle 
region (M15) or N-terminus (N11) of CFH. Data of a representative experiment are shown. 
 
Figure 2. Serum autoantibody titers in the patients during disease progression. 
(A) Patient 1 was diagnosed with aHUS and later experienced disease recurrences, during 
which he received plasma exchanges (horizontal bars). CFH autoantibody titers (in arbitrary 
units/ml) are shown for several available time points as vertical bars. As reference, a plasma 
sample taken at month 10 was used (1000 AU/ml). Additional information about the 
treatment is indicated above by arrows. (B) and (C) show the titers during disease follow-up 
in patients 2 and 3, respectively, in relation to the reference plasma of patient 1. *The CFH 
autoantibody titer of these samples was determined retrospectively. PEx: plasma exchange, 
FFP: fresh frozen plasma. 
 
Figure 3. In vitro hemolytic activity of autoantibody positive plasma samples using sheep 
erythrocyte lysis assay. 
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(A) Sheep erythrocytes suffer dose-dependent lysis in the presence of autoantibody positive 
patient plasma as compared to normal human plasma. Autoantibody titers are indicated in 
brackets; control samples had values <100 AU/ml. Hemoglobin release was measured in the 
supernatant by absorbance at 414 nm after 30 min incubation at 37°C. Data represent mean 
values of duplicate measurements from a representative experiment and are expressed as % of 
total lysis achieved by H2O. (B) Plasma samples lacking CFHR1 and CFHR3 cause no 
hemolysis if there are no CFH autoantibodies present. CFHR1+/CFHR3+ normal plasma and 
plasma of the autoantibody positive, CFHR1-/CFHR3- patient 1 are shown as negative and 
positive controls, respectively. The addition of 20 µg/ml C18 mAb results in enhanced lysis in 
all samples (filled bars). (C) C-terminally binding mAbs, which have overlapping epitopes 
and compete with the autoantibodies for CFH binding, cause enhanced hemolysis of sheep 
erythrocytes (mAbs C02, C14 and C18) incubated with 10% C2-depleted human plasma (used 
to exclude classical pathway mediated lysis). In contrast, CFH-specific mAbs that bind 
outside the C-terminal domains (SCRs 19-20) cause no hemolysis (mAbs N11, N22, M12, 
M13 and M16). 
 
Figure 4. The in vitro hemolytic activity of patients’ plasma correlate with the 
autoantibody titer. 
(A) Patient 1 displayed persisting high autoantibody titers and also high hemolytic activity. 
These complement active samples were only available when the patient was already on 
peritoneal dialysis. Both C3 levels (0.8-1.3 mg/ml) and CFH levels (102-133%) were in the 
normal range in these samples. (B) Hemolytic activity of plasma samples of patient 2 taken at 
various time points. After the acute phase, both autoantibody titers and hemolytic activities 
are low. Sample 1 had lower C3 level (0.42 mg/ml), whereas C3 levels were normal in the 
other samples (1.19-1.51 mg/ml). CFH levels were in the normal range (105-123%), except 
for sample 2 (61%). (C) Comparison of hemolytic activity of two plasma samples of a patient, 
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described before [8], with high and low CFH autoantibody titers. C3 levels were 0.85 mg/ml 
and 1.3 mg/ml, and CFH levels 95% and 155% in sample 1 and 2, respectively. Plasma 
samples were used at 20% dilution in (A) and (B), and at 30% in (C). 
 
Figure 5. IgG-depletion provides direct evidence for the CFH function-inhibitory effect 
of the autoantibodies. 
(A) Depletion of IgG by incubating plasma samples with Protein G for various time periods 
results in artificial titer reduction and reduced hemolytic activity. A representative experiment 
with samples of patient 2 is shown. (B) All three analyzed patients’ samples showed 
hemolytic activity reduced to the control level after IgG-depletion. Addition of CFH blocking 
mAb C18 to the depleted plasma reverts the beneficial effect of IgG-depletion (Plasma ΔIgG 
+ C18), indicating that IgG-depletion removes CFH inhibitory antibodies but the plasma 
samples still have a functional complement system. 
 
Figure 6. Analysis of CFH:autoantibody complexes in patients’ plasma 
(A) The indicated dilutions of plasma samples, patient 2/I (autoantibody titer 1325 AU/ml), 
patient 2/II (361 AU/ml), patient 3/I (883 AU/ml) and 3/II (867 AU/ml), were incubated in 
wells coated with the anti-CFH mAb M15 as catch antibody, and the bound 
CFH:autoantibody complexes were detected with anti-human IgG. As a control, normal 
human plasma (NHP) is also shown. (B) Immune complexes (left panel) are absent from IgG-
depleted plasma (empty bars, ΔIgG), measured as in A. As controls, binding of anti-IgG to 
plasma samples incubated in wells without anti-CFH mAb coat and the presence of CFH in 
the plasma samples (right panel) are shown. (C) The mAb C18 captures free CFH only, due to 
overlapping binding sites with the autoantibodies, thus falsely indicates low CFH levels if the 
autoantibody titer is high. In contrast, mAb M15 detects free CFH as well as CFH:IgG 
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complexes, thus comparison of CFH levels determined using the two mAbs allows an 
estimate of free and complexed CFH. 
 






